Nuzenio

Structure Therapeutics Reports

Structure Therapeutics Reports news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 19 latest news signals 5 publisher sources 100/100 entity strength

Latest news

Citigroup Cuts Structure Therapeutics (NASDAQ:GPCR) Price Target to $97.00 - MarketBeatMarketBeat · Fri, 07 Aug 2026 20:34:13 GMTStructure Therapeutics (GPCR) awards options and RSUs to its CCO - Stock TitanStock Titan · Fri, 07 Aug 2026 20:09:08 GMTStructure Therapeutics Inc. (GPCR) files initial Form 3 for CCO - Stock TitanStock Titan · Fri, 07 Aug 2026 20:07:09 GMTStructure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeatMarketBeat · Fri, 07 Aug 2026 08:20:29 GMTStructure Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Thu, 06 Aug 2026 23:41:33 GMTStructure Therapeutics posts $106.2M Q2 net loss, $1.34B cash; doses first patients in Phase 3 aleniglipron - TradingViewTradingView · Thu, 06 Aug 2026 20:35:29 GMTStructure Therapeutics Inc. 2026: Revenue ($107.41M), Net income ($106.16M), EPS ($0.49) — 10-Q Summary - TradingViewTradingView · Thu, 06 Aug 2026 20:35:07 GMTStructure Therapeutics (Nasdaq: GPCR) reports $182.1M H1 loss and $1.34B cash - Stock TitanStock Titan · Thu, 06 Aug 2026 20:29:54 GMT

Timeline

Fri, 07 Aug 2026 20:34:13 GMTCitigroup Cuts Structure Therapeutics (NASDAQ:GPCR) Price Target to $97.00 - MarketBeat
Fri, 07 Aug 2026 20:09:08 GMTStructure Therapeutics (GPCR) awards options and RSUs to its CCO - Stock Titan
Fri, 07 Aug 2026 20:07:09 GMTStructure Therapeutics Inc. (GPCR) files initial Form 3 for CCO - Stock Titan
Fri, 07 Aug 2026 08:20:29 GMTStructure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Thu, 06 Aug 2026 23:41:33 GMTStructure Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingView
Thu, 06 Aug 2026 20:35:29 GMTStructure Therapeutics posts $106.2M Q2 net loss, $1.34B cash; doses first patients in Phase 3 aleniglipron - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Structure Therapeutics Reports.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

5 distinct publisher/source names are currently connected to this entity page.